SLC2A1 and Alzheimer disease: Because Alzheimer’s disease is characterized by reduced GLUT1 at the BBB and a reduction of glucose transport [129], this strategy of rapid glycemic increase after fasting holds the potential to treat Alzheimer’s disease via upregulating GLUT1.